Clinical Trial Update: Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of JNJ-64304500 in moderately to severely active Crohn's disease has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• JNJ-64304500

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Crohn Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-02-17